ArticleHeadache2025
Early nimodipine treatment in reversible cerebral vasoconstriction syndrome: A serial transcranial Doppler study.
Article in Headache, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Reversible cerebral vasoconstriction syndrome: a medical challenge in the peripartum period requiring a multimodal approach: a case report.AJOG global reports · 2026Article
- Review
- Early nimodipine treatment in reversible cerebral vasoconstriction syndrome: A serial transcranial Doppler study.Headache · 2025Article
- Reversible cerebral vasoconstriction syndrome-related headache and delayed cerebral infarction: a mini review.Frontiers in neuroscience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
OBJECTIVES/
backgroundAlthough nimodipine is commonly used to treat reversible cerebral vasoconstriction syndrome (RCVS), its disease-modifying effects are not yet understood. We prospectively investigated the effect of nimodipine and treatment initiation timing on the prevention of worsened vasoconstriction in patients with angiogram-proven RCVS.
methodsIn this prospective cohort study, we recruited patients with angiogram-proven RCVS who visited a single headache clinic between June 2019 and November 2021. To evaluate the mean flow velocities (MFVs) of the middle cerebral arteries, patients underwent transcranial Doppler at baseline and were then serially followed up after 10, 20, 30, and 90 days. Oral nimodipine treatment was initiated after the baseline transcranial Doppler study. We estimated the worsening of vasoconstriction using the area of total time spent with MFVs above the baseline value ("MFV area").
resultsA total of 32 patients (51.5 ± 10.3 years old, 91% female) completed this study. During nimodipine treatment, MFVs gradually decreased in 94% (n = 30/32) of patients (p < 0.001). The MFVs in the early treatment group (<7 days after onset) were lower than the untreated baseline MFVs of the late treatment group (≥7 days) at the same time point after onset (69.8 ± 19.4 vs. 86.1 ± 23.7 cm/s, p = 0.032). Earlier treatment with nimodipine correlated with reduced MFV area (r = 0.37, p = 0.038), and this relationship remained significant after adjustment for covariates (β = 58.46, 95% confidence interval = 2.31-114.62, p = 0.041).
conclusionOur study shows an independent association between the timing of oral nimodipine administration and exacerbation of cerebral vasoconstriction in patients with RCVS, suggesting that early administration of nimodipine may have a role in mitigating vasoconstriction. A potential disease-modifying role of nimodipine should be tested in future studies using a hypothesis-testing design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.